EBIT at other companies
Other financials
Where this comes from
Calculated from Nektar Therapeutics’s reported figures.
Plus components not separately reported this period.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's EBIT?
- Nektar Therapeutics (NKTR) reported EBIT of -$39.05M in Q1 2026.
- How has Nektar Therapeutics's EBIT changed year-over-year?
- Nektar Therapeutics's EBIT increased by 12.3% year-over-year, from -$44.54M to -$39.05M.
- What is the long-term trend for Nektar Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Nektar Therapeutics's EBIT has grown at a -25.1% compound annual growth rate (CAGR), from -$446.1M to -$140.1M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.